Met Life Investment Management, LLC Glycomimetics Inc Transaction History

Met Life Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $46,578 - $213,759	-16,635 Closed	0 $0
Q2 2019 Jul 12, 2023	BUY	$10.6 - $13.12 $176,331 - $218,251	16,635 New	16,635 $198,000
Q1 2019 Jul 13, 2023	BUY	$9.96 - $13.44 $165,684 - $223,574	16,635 New	16,635 $207,000
Q4 2018 Jul 13, 2023	BUY	$8.47 - $14.71 $140,898 - $244,700	16,635 New	16,635 $157,000
Q4 2018 Mar 22, 2023	SELL	$8.47 - $14.71 $77,712 - $134,964	-9,175 Reduced 35.55%	16,635 $157,000
Q4 2018 Feb 14, 2019	SELL	$8.47 - $14.71 $77,712 - $134,964	-9,175 Reduced 35.55%	16,635 $158,000
Q3 2018 Jul 13, 2023	BUY	$13.7 - $17.12 $227,899 - $284,791	16,635 New	16,635 $239,000
Q3 2018 Mar 22, 2023	BUY	$13.7 - $17.12 $353,597 - $441,867	25,810 New	25,810 $371,000
Q3 2018 Nov 14, 2018	BUY	$13.7 - $17.12 $125,697 - $157,076	9,175 Added 55.15%	25,810 $372,000
Q2 2018 Aug 15, 2018	BUY	$14.63 - $19.19 $243,370 - $319,225	16,635 New	16,635 $268,000

28.9M

51K

1.4K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.6M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.